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SUMMARY
Breast cancer (BC) is the most common malignancy among women. Therapeutic 
options are based on disease staging, histopathological characteristics, age, and others. 
The objective of the present study is to carry out an update of the concepts and defini-
tions of radiotherapy (RT) in conservative treatment of early-stage breast cancer, with 
emphasis on indications, contraindications, RT dose fractionation schedules (classic, 
hypofractionated and partial breast irradiation), adjuvant RT in ductal carcinoma in situ 
(DCIS) and molecular predictors of recurrence. MEDLINE, SciELO and Cochrane data-
bases were used for article selection. Adjuvant RT is indicated for patients with BC who 
underwent conservative breast surgery. In selected patients, hypofractionated or partial 
breast irradiation can be used. Adjuvant RT should be provided for all patients with 
DCIS. The correlation of RT and molecular predictors of local and systemic recurrence 
are not yet well-known. 
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INTRODUCTION
Breast cancer is the most common malignancy among 
women (with the exception of non-melanoma skin can-
cers). According to data from the Instituto Nacional do 
Câncer (INCA), in Brazil, 49,240 new cases were estimat-
ed for the year 2010, which corresponds to an estimated 
risk of 65 new cases per 100,000 women1.
Early diagnosis is a major prognostic factor and the 
therapeutic choice will depend on the clinical stage of 
the disease, pathological characteristics, clinical condi-
tions, age and the patient’s wishes.
Tumors staged as 0 (in situ) to IIB are considered as 
initial breast cancer according to the TNM classification of 
the American Joint Committee on Cancer.
For many years, the radical mastectomy proposed by 
Halsted in 1894 was the standard treatment for breast can-
cer regardless of any associated factors. However, from the 
80’s on, there was a change in the therapeutic approach, 
following the trend of more conservative treatments, but 
without compromising oncological safety. 
Breast conservation, which is based on the surgical 
excision of the tumor (sectorectomy or quadrantectomy) 
and axillary management (with or without sentinel node 
axillary dissection) followed by radiotherapy (RT), is now 
the standard local treatment for the disease in early stages.
This study presents an update of concepts and defini-
tions of radiotherapy (RT) in conservative treatment of 
early-stage breast cancer with emphasis on indications, 
contraindications, modalities, dose and fractionation RT 
(classic scheme, hypofractionated and partial breast irra-
diation), adjuvant RT in ductal carcinoma in situ and RT 
association with molecular predictors of recurrence.
METHODS
This is an update on the proposed theme using the MED-
LINE, SciELO and Cochrane databases. As a search engine, 
the keywords “breast cancer”, “radiotherapy”, “early stage” 
and “conservative treatment” were used for the selection of 
available key articles, with emphasis on the last 10 years.
Randomized phase III prospective trials were especial-
ly considered, as well as those considered fundamental in 
therapeutic decision-making.
RADIOTHERAPY IN THE CONSERVATIVE TREATMENT 
At least six randomized trials compared radical mas-
tectomy with conservative surgery followed by RT and 
showed an equivalent overall survival rate between these 
therapeutic modalities2. Updates with twenty years of 
follow-up of studies from the National Cancer Institute 
of Milan3 and the National Surgery Adjuvant Breast and 
Bowel Project (NSABP) B064 corroborated these results.
It is important to emphasize that since these studies 
were initiated, there has been considerable development in 
imaging techniques for tumor location, in addition to the 
recommendation of the requirement to obtain free resec-
tion margins in order to reduce the risk of local recurrence, 
which was previously not considered necessary. Moreover, 
the use of adjuvant hormone therapy (HT) has reduced the 
risk of local recurrence and increased survival5.
Within this rationale, some studies have examined 
the role of RT after breast-conserving surgery in women 
with early-stage breast cancer, in order to identify a sub-
group of patients that would not benefit from RT after 
surgery and HT.
A Canadian study6 randomized 769 patients aged 50 
years or more, T1-T2 tumors and negative lymph nodes 
to receive breast RT and HT with tamoxifen versus HT 
with tamoxifen. At 5.6 years of median follow-up, it 
was observed that local recurrence was 0.6% and 7.7% 
(p < 0.001) for the first and second groups, respectively.
The Cancer and Leukemia Group B, Radiation Ther-
apy Oncology Group e Eastern Cooperative Oncology 
Group7 randomized 639 patients aged 70 years or more, 
clinical stage I (T1N0M0), with positive estrogen recep-
tors to receive RT and HT or HT exclusively. There was 
no difference in distant metastasis and overall survival at 
five years. There was better local control in patients who 
received combined adjuvant therapy (local recurrence 
rate of 1% RT-HT versus 4% HT, p < 0.001). Fifty-seven 
percent of women eligible for the study refused partici-
pation, as they did not agree to receive HT without RT. 
Despite these results, some authors question whether an 
absolute difference of only 3% in local control rate would 
justify the cost-benefit of radiotherapy in this group of 
patients. However, if one takes into account the short 
follow-up period of this study (5 years) in relation to life 
expectancy of women of 10 or 15 years, the gain in abso-
lute terms would be more robust.
Furthermore, with the advent of modern RT tech-
niques (tridimensional conformal 3D-CRT - or inten-
sity modulated RT - IMRT) a better sparing of adjacent 
normal tissues can be achieved (heart, lungs, esophagus, 
bone and skin) with more homogeneous dose distribu-
tion, substantially reducing treatment toxicity8.
Finally, mastectomy with preservation of the papil-
lary-areola complex, which, despite being defended by 
some authors as oncological surgery9 should be consid-
ered as conservative (there is no level I evidence yet to 
ensure the oncological safety of mastectomy with pres-
ervation of papillary-areola complex, also called adeno-
mastectomy) therefore, capable of receiving adjuvant RT. 
In fact, a long-term study of the Karolinska Institute10 fol-
lowing 12 years of evolution of patients treated with this 
technique showed a 28% chance of recurrence x 8.5% in 
favor of patients who received postoperative RT.
Thus, whole breast irradiation is recommended for all 
women undergoing conservative surgery for breast can-
cer in initial stages.
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CONTRAINDICATIONS TO CONSERVATIVE TREATMENT 
Conservative treatment in breast cancer is possible for 
most women; however, it is not applicable to all. Contra-
indications to conservative treatment are subdivided into 
absolute and relative.
ABSOLUTE CONTRAINDICATIONS
t Persistent positive margins after several attempts 
at re-excision;
t Multicentric disease – two or more primary tu-
mors in separate quadrants of the breast;
t Microcalcifications with diffuse aspects on the 
mammography, suggesting multicentricity;
t Pregnancy, although it may be possible to perform 
a conservative surgery in the last trimester and RT 
after delivery.
RELATIVE CONTRAINDICATIONS 
t Connective tissue diseases, particularly sclero-
derma or syndromes that have a high chance of 
cutaneous involvement (higher rates of dermal 
complications);
t Large tumor in small breast, when surgery can re-
sult in a significant esthetic defect;
t Women with large or pendulous breasts may be 
submitted to RT as long as it is technically possible 
to obtain adequate dose homogeneity;
t History of previous RT in the breast region (e.g., 
Hodgkin’s disease or conservative treatment of ip-
silateral breast).
t Premenopausal patients who are carriers of the 
BRCA1/2 mutation.
In many situations, patients that are candidates for 
conservative treatment are submitted to a radical mas-
tectomy due to the use of inappropriate criteria. Age, 
histological subtypes, immunohistochemical character-
istics, metastasis to axillary lymph nodes and internal 
mammary chain, tumor location and positive family his-
tory do not contraindicate conservative therapy. In ad-
dition to these parameters, many patients refuse conser-
vative treatment due to stigma/fear of RT. Nevertheless, 
removal of patients from their usual activities for 5 or 6 
weeks to undergo RT, or the distance from her home to 
RT service are also variables that influence the patient’s 
therapeutic decision11.
RADIOTHERAPY MODALITIES, DOSE AND FRACTIONATION
CLASSIC SCHEME 
Classically, the modality used for breast RT is teletherapy. 
There are different dose and fractionation schemes used, 
although most of the major world centers use from 4500 
to 5000 cGy of total dose to 180 to 200 cGy/fraction, 5 
days a week.
Using the argumentation that the tumor bed is the site of 
most local recurrences12,13 and that greater control could be 
achieved with a higher dose (booster) in the quadrant ini-
tially affected by the tumor (including the surgical scar) with 
no significant increase in morbidity, this practice began to be 
considered. The actual impact of the boost in conservative 
treatment was directly evaluated in two randomized trials.
In the Lyon study14, 1,024 women with invasive 
tumors ≤ 3 cm in diameter, submitted to local excision and 
axillary dissection (98% of negative margins) plus whole 
breast RT with a dose of 5000  cGy were randomized to 
receive 1000 cGy boost dose in the tumor bed or no ad-
ditional treatment. With a median follow-up of 3.3 years, 
the rate of local failure at 5 years was 3.6% and 4.5%, with 
and without boost, respectively (p = 0.044). 
The European Organization for Research and Treat-
ment of Cancer (EORTC)15 randomized 5,569 women 
with stage I or II breast cancer who underwent conserva-
tive surgery and whole breast RT with a dose of 5000 cGy, 
between a boost of 1600 to 2600  cGy versus no addi-
tional treatment. The rate of local recurrence in five years 
was significantly lower in women who received boost 
(4.3% vs. 7.3%) being more significant in women under 
45 years (10.2% vs. 19.2%). There were no differences in 
overall survival and survival free of distant metastases in 
both groups. At the ten-year update of this study16, the 
use of boost maintained the gain of local control benefit 
(local failure of 10.2% without boost versus 6.2% with it; 
p < 0.0001) in all age groups of the sample. 
The boost dose can be delivered with teletherapy or 
brachytherapy. The first more commonly uses electrons 
with variable energy, depending on breast size and tumor 
bed depth; in the latter, Iridium-192 can be used by plac-
ing plastic catheters or needles, usually using two plans 
for complete coverage of the target-volume. They can be 
placed at the time of surgery, with subsequent loading of 
radioactive sources. Use of external beam radiation thera-
py or teletherapy with photons can also be prescribed for 
boost planning.
The best way to determine the boost location is through 
visualization of metal clips placed during surgery. In their 
absence, imaging tests (ultrasound, mammography and/or 
breast MRI) can be used as a guide to the location of the 
tumor bed, plus the information of the surgical scar. A 
common practice is to treat the whole quadrant of the pri-
mary lesion site.
Moreover, this is a challenging practice for the Bra-
zilian radiation oncologist, who almost always treats the 
patient after conservative surgery with immediate recon-
struction without proper demarcation by metal clips. The 
scar reference is lost, as it will not necessarily be in the 
initially affected quadrant and it is difficult to establish if 
the margin of the parenchyma to receive a boost dose is 
still in the projection of the quadrant in question. 
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HYPOFRACTIONATED SCHEME 
Around 15 years ago, the first studies were designed to 
propose a hypofractionated treatment regimen (short-
er treatment time with higher dose per fraction). One 
would be able to hypothetically optimize the treatment 
period using this promising technique. Thus, problems 
such as scarcity of RT services and equipment and poor 
access of patients coming from distant places to receive 
RT applications could be less important in the therapeu-
tic decision. Additionally, hypofractionated treatment 
would reduce waiting lists in public healthcare, such as 
in Brazil.
A Canadian study17 randomized 1,234 women sub-
mitted to conservative treatment, with negative resection 
margins and negative lymph nodes to receive 4250 cGy 
total dose in 16 fractions (22 consecutive days), or 
5000 cGy in 25 fractions (35 consecutive days). With a 
median follow-up of 69 months, local recurrence-free 
survival at five years was similar between the two arms 
(97.2% vs. 96.8%) as well as overall and disease-free sur-
vival, with 77% of excellent or good cosmetic results in 
both arms. In this study update18, with twelve years of 
follow-up, recurrence rates were similar: 6.7% for the 
standard treatment versus 6.2% for hypofractionated, 
with around 70% of excellent or good cosmetic results in 
both groups.
So this is a new model that can be used in selected 
patients, which must be avoided in situations where there 
was prior chemotherapy, when it is necessary to treat 
regional lymph nodes with RT, in immediate plastic re-
constructions and in large breasts. The role of boost in 
hypofractionated schemes is uncertain, since at the time 
of the Canadian study design its real significance was not 
known. However, in the START British studies, use of 
boost as well as irradiation of the regional lymph nodes 
were allowed19,20.
PARTIAL BREAST IRRADIATION
Based again on the rationale that the majority of recur-
rences after conservative treatment occurs in the primary 
tumor quadrant, combined with the social aspects men-
tioned above (distance from the residence to the RT ser-
vice etc.), the possibility to perform RT directed only to 
the tumor bed and not to the whole breast in selected 
cases has been suggested and tested in studies with vary-
ing levels of evidence. This technique was named as ac-
celerated partial breast irradiation (APBI).
Several techniques have been applied for APBI, from 
brachytherapy with high or low dose rates (intracavitary 
or interstitial), intraoperative RT (IORT) with electrons 
or orthovoltage or even external RT.
The American Society for Therapeutic Radiology and 
Oncology (ASTRO) in a recent publication21 listed its nor-
mative consensuses concerning APBI, inferring the criteria 
and characteristics of patients that are candidates for this 
new therapeutic modality. This publication is considered 
the main guideline for APBI and it admits the treatment 
of some patients out of investigation protocols (Table 1).
Similarly, the Groupe Européen de Curiethérapie and 
European Society for Therapeutic Radiology and Oncol-
ogy22 also published their recommendations for APBI, 
categorizing patients into low risk, intermediate risk and 
high risk (good candidates, possible candidates and po-
tential contraindications for APBI, respectively).
Table 1 – Patient selection for accelerated partial breast irradiation (APBI) according to the American Society for Therapeutic 
Radiology and Oncology (ASTRO)21
Criteria used
APBI
Suitable
(all factors)
Cautionary
(any factor)
Unsuitable (study protocols)
(any factor)
Patient age ≥ 60 yrs. 50-59 yrs. < 50 yrs.
Tumor size Up to 2 cm 2 to 3 cm > 3 cm
Histological type IDC ILC DCIS
Histological/nuclear grade Any – –
Lymphovascular invasion Negative Focal Extensive
Estrogen receptor Positive Negative –
DCIS/ intraductal extension Not allowed Up to 3 mm > 3 cm
Surgical margins Negative < 2 mm Positive
Presentation Unicentric – –
Lymph node status Negative Negative Positive
BRCA Negative – Positive
Neoadjuvant CT Not allowed Not allowed Yes
IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; DCIS, ductal carcinoma in situ; CT, chemotherapy.
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Perhaps the main benefit of using these techniques is 
to reduce the total treatment time, which rather than being 
performed for six weeks (conventional RT), can be carried 
out at the time of surgery to remove the tumor (IORT) or 
up to one week after the surgical procedure (brachyther-
apy). Although all the studies presented very promising 
results, follow-up of all series is relatively short and the 
treatment is applied only to highly selected patients.
ADJUVANT RADIOTHERAPY IN DUCTAL CARCINOMA IN SITU 
Ductal carcinoma in situ (DCIS) is traditionally classified 
taking the architectural pattern into account (comedone-
crosis, cribriform, micropapillary, papillary or solid) and 
represents a distinct set of proliferative lesions with po-
tential heterogeneous invasiveness. Thus, it is necessary to 
identify the lesions most likely to be aggressive in order to 
establish the appropriate treatment plan.
At the era of radical mastectomy, cure rates approached 
98%. With the rise of conservative treatment for invasive 
carcinomas, this strategy was introduced and considered 
the standard approach for DCIS, although there have been 
no prospective randomized trials comparing radical mas-
tectomy and conservative treatment in this specific popu-
lation.
Three studies have shown the benefit of adding adju-
vant RT in patients with DCIS undergoing breast-conserv-
ing surgery. The NSABP B-17 study23 included 818 patients 
who were randomized between sole surgical treatment or 
surgery associated with whole breast RT with a total dose 
of 5000 cGy. The primary outcome was local, invasive or 
intraductal recurrence. With 12 years of follow-up, the use 
of RT reduced the cumulative local recurrence rate (16% 
versus 32%). When stratified in terms of invasive and non-
invasive recurrences, this gain was observed in both sub-
groups, although the reduction was greater for the invasive 
than for the non-invasive ones (16.8% vs. 7.7% and 14.6% 
vs. 8%, respectively). There was no impact on overall and 
cancer-specific survival.
In another study of similar design (European Orga-
nization for Research and Treatment of Cancer - EORTC 
10853)24, 1,010 patients with DCIS treated with conserva-
tive surgery with tumors ≤ 5 cm were randomized between 
whole breast RT (dose of 5000 cGy) or clinical follow-up. 
After 4.3 years of follow-up, those who received RT had 
lower rates of invasive (4.8% vs. 8%) and non-invasive re-
currence (5.8% vs. 8.8%) compared to those without adju-
vant therapy.
The cooperative study (England - Australia - New 
Zealand)25, of which update was presented at the 32nd San 
Antonio Breast Cancer Symposium26 randomized 1,701 
patients submitted to surgery for DCIS with clear mar-
gins in the following groups: surgery alone, surgery with 
RT, surgery with tamoxifen, surgery with radiotherapy 
and tamoxifen. After 53 months of mean follow-up, RT 
decreased the incidence of ipsilateral invasive disease 
(hazard ratio of 45%) and ipsilateral DCIS (hazard ratio 
of 36%). Use of hormone therapy did not reduce the in-
cidence of ipsilateral invasive tumors, but decreased the 
overall DCIS recurrence (hazard ratio of 68%). 
Although there are criticisms to the NSABP B-17 
and EORTC 10853 studies due to the fact that patho- 
logic and mammographic assessments are not in accor-
dance with current standards, there is a clear advantage 
in using RT to reduce the risk of local recurrence when 
compared with surgery alone. There are no concrete data 
in the literature capable of selecting subgroups of patients 
with DCIS who would benefit little or not at all from RT 
after conservative surgery. 
MOLECULAR PREDICTORS OF RECURRENCE
Traditionally, the decision of the best approach for the 
treatment of patients with breast cancer is based on clini-
cal and pathological characteristics and staging (TNM), 
surgical margin status, histology and patient age. How-
ever, with the increasing knowledge of molecular biology, 
the concept that breast cancer represents a heterogeneous 
group of diseases is increasingly accepted and researchers 
are now investigating whether these particular molecules 
could modify the employed therapeutic strategy.
The most recent classification of breast tumors with 
the participation of molecular biology tends to subdivide 
them into luminal categories A or B, HER-2 positive or 
negative and triple negative. Likewise, use of molecular 
predictors that assess gene expression could also be used 
in assessing the risk of local recurrence. 
Although the first published studies helped in the deci-
sion regarding the type of adjuvant systemic treatment to 
be used, there are as yet no clinical trials that correlate the 
role of RT with molecular predictors of local and systemic 
recurrence27, 28.
CONCLUSION
Indications and contraindications of adjuvant RT in the 
therapeutic approach of patients with early-stage breast 
cancer submitted to conservative treatment are well-defined 
in the literature. For selected patients, hypofractionated RT 
schemes or partial breast irradiation can be employed, as 
there is evidence that this option is equivalent in terms of 
local control to the classic model of breast irradiation.
Adjuvant RT in DCIS should be offered to all patients, 
especially younger ones, by reducing the risk of local re-
currence. There are no concrete data in the literature ca-
pable of selecting subgroups of patients with DCIS who 
would benefit little or not at all from RT after conservative 
surgery.
Correlation between the role of RT with molecular 
predictors of local and systemic recurrence should be fur-
ther studied.
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